BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho AF, Maes M. A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions. CNSNDDT 2019;18:124-40. [DOI: 10.2174/1871527317666181119115532] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Roomruangwong C, Sirivichayakul S, Carvalho AF, Maes M. The uterine-chemokine-brain axis: menstrual cycle-associated symptoms (MCAS) are in part mediated by CCL2, CCL5, CCL11, CXCL8 and CXCL10. Journal of Affective Disorders 2020;269:85-93. [DOI: 10.1016/j.jad.2020.03.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Maes M, Sirivichayakul S, Kanchanatawan B, Vodjani A. Upregulation of the Intestinal Paracellular Pathway with Breakdown of Tight and Adherens Junctions in Deficit Schizophrenia. Mol Neurobiol 2019;56:7056-73. [PMID: 30972627 DOI: 10.1007/s12035-019-1578-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
3 Al-Hakeim HK, Almulla AF, Al-Dujaili AH, Maes M. Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia. Curr Top Med Chem. 2020;20:747-758. [PMID: 31994463 DOI: 10.2174/1568026620666200128143948] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
4 Thisayakorn P, Thipakorn Y, Tantavisut S, Sirivichayakul S, Maes M. Delirium due to hip fracture is associated with activated immune-inflammatory pathways and a reduction in negative immunoregulatory mechanisms. BMC Psychiatry 2022;22:369. [PMID: 35641947 DOI: 10.1186/s12888-022-04021-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Almulla AF, Al-Hakeim HK, Maes M. Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophrenia. CNS Spectr 2021;26:368-77. [PMID: 32431263 DOI: 10.1017/S1092852920001182] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
6 Maes M, Sirivichayakul S, Kanchanatawan B, Vodjani A. Breakdown of the Paracellular Tight and Adherens Junctions in the Gut and Blood Brain Barrier and Damage to the Vascular Barrier in Patients with Deficit Schizophrenia. Neurotox Res 2019;36:306-22. [PMID: 31077000 DOI: 10.1007/s12640-019-00054-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 13.7] [Reference Citation Analysis]
7 Maes M, Sirivichayakul S, Kanchanatawan B, Carvalho AF. In schizophrenia, psychomotor retardation is associated with executive and memory impairments, negative and psychotic symptoms, neurotoxic immune products and lower natural IgM to malondialdehyde. World J Biol Psychiatry 2020;21:383-401. [PMID: 32031479 DOI: 10.1080/15622975.2019.1701203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
8 Modugula H, Kumar A. Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression. CNS Neurol Disord Drug Targets 2020;19:109-14. [PMID: 32124704 DOI: 10.2174/1871527319666200303120147] [Reference Citation Analysis]
9 Zakowicz P, Pawlak J, Kapelski P, Wiłkość-Dębczyńska M, Szałkowska A, Twarowska-Hauser J, Rybakowski J, Skibińska M. Genetic association study reveals impact of interleukin 10 polymorphisms on cognitive functions in schizophrenia. Behav Brain Res 2022;419:113706. [PMID: 34875307 DOI: 10.1016/j.bbr.2021.113706] [Reference Citation Analysis]
10 Al-Dujaili AH, Mousa RF, Al-Hakeim HK, Maes M. High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments. Schizophr Bull 2021;47:530-41. [PMID: 32971537 DOI: 10.1093/schbul/sbaa136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Bosnjak Kuharic D, Bozina N, Ganoci L, Makaric P, Kekin I, Prpic N, Bozina T, Rojnic Kuzman M. Association of HSPA1B genotypes with psychopathology and neurocognition in patients with the first episode of psychosis: a longitudinal 18-month follow-up study. Pharmacogenomics J 2020;20:638-46. [DOI: 10.1038/s41397-020-0150-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Matsumoto AK, Maes M, Supasitthumrong T, Maes A, Michelin AP, de Oliveira Semeão L, de Lima Pedrão JV, Moreira EG, Kanchanatawan B, Barbosa DS. Deficit schizophrenia and its features are associated with PON1 Q192R genotypes and lowered paraoxonase 1 (PON1) enzymatic activity: effects on bacterial translocation. CNS Spectr 2021;26:406-15. [PMID: 32638685 DOI: 10.1017/S1092852920001388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
13 Almulla AF, Al-hakeim HK, Abed MS, Carvalho AF, Maes M. Chronic fatigue and fibromyalgia symptoms are key components of deficit schizophrenia and are strongly associated with activated immune-inflammatory pathways. Schizophrenia Research 2020;222:342-53. [DOI: 10.1016/j.schres.2020.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Li L, Liu J, She H. Targeting Macrophage for the Treatment of Amyotrophic Lateral Sclerosis. CNSNDDT 2019;18:366-71. [DOI: 10.2174/1871527318666190409103831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Almulla AF, Al-Rawi KF, Maes M, Al-Hakeim HK. In schizophrenia, immune-inflammatory pathways are strongly associated with depressive and anxiety symptoms, which are part of a latent trait which comprises neurocognitive impairments and schizophrenia symptoms. J Affect Disord 2021;287:316-26. [PMID: 33812245 DOI: 10.1016/j.jad.2021.03.062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Magnusen AF, Hatton SL, Rani R, Pandey MK. Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease. Front Neurol 2021;12:636139. [PMID: 34239490 DOI: 10.3389/fneur.2021.636139] [Reference Citation Analysis]
17 Moustafa SR, Al-Rawi KF, Stoyanov D, Al-Dujaili AH, Supasitthumrong T, Al-Hakeim HK, Maes M. The Endogenous Opioid System in Schizophrenia and Treatment Resistant Schizophrenia: Increased Plasma Endomorphin 2, and κ and μ Opioid Receptors Are Associated with Interleukin-6. Diagnostics (Basel) 2020;10:E633. [PMID: 32858974 DOI: 10.3390/diagnostics10090633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
18 Morrens M, Overloop C, Coppens V, Loots E, Van Den Noortgate M, Vandenameele S, Leboyer M, De Picker L. The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis. Mol Psychiatry 2022. [PMID: 35484245 DOI: 10.1038/s41380-022-01582-y] [Reference Citation Analysis]
19 Roomruangwong C, Noto C, Kanchanatawan B, Anderson G, Kubera M, Carvalho AF, Maes M. The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia. Mol Neurobiol. 2019;. [PMID: 31473906 DOI: 10.1007/s12035-019-01737-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
20 Maes M, Sirivichayakul S, Matsumoto AK, Maes A, Michelin AP, de Oliveira Semeão L, de Lima Pedrão JV, Moreira EG, Barbosa DS, Geffard M, Carvalho AF, Kanchanatawan B. Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity. Mol Neurobiol 2020;57:2333-45. [DOI: 10.1007/s12035-020-01882-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
21 Maes M, Kanchanatawan B. In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life. CNS Spectr 2021;:1-10. [PMID: 33843548 DOI: 10.1017/S1092852921000419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ivanovska M, Abdi Z, Murdjeva M, Macedo D, Maes A, Maes M. CCL-11 or Eotaxin-1: An Immune Marker for Ageing and Accelerated Ageing in Neuro-Psychiatric Disorders. Pharmaceuticals (Basel) 2020;13:E230. [PMID: 32887304 DOI: 10.3390/ph13090230] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]